Ecology and Evolution of Antibiotic Resistance Unit, Microbiology Department, Institut Pasteur

Head of the Unit, research director

28, Rue du Dr Roux, 75724 Paris, France

33 1 45 68 89 96



Background and expertise of the representative

Philippe Glaser is heading with Thierry Naas a joint Unit between the Institut Pasteur and the Bicêtre Hospital, which aims to characterize carbapenem resistant Enterobacteriaceae, considered by WHO as “critical” priority pathogens for which novel antibiotics are urgently needed. He is an expert in bacterial evolution and genomics with a focus on the emergence and the global dissemination of antibiotic resistance and in bacterial physiology. His research is focusing on Klebsiella pneumoniae and Escherichia coli producing carbapenemases. Philippe Glaser is author of 152 publications with an H factor of 55. He is also director of the Institut Pasteur program “Fighting Antibiotic Resistance” (https://research.pasteur.fr/en/program_project/fighting-antibiotic-resistance/). This program gathers 34 teams from six departments of the Parisian campus and integrates all aspects of research on antibiotic resistance, from the development of new molecules to alternative strategies to fight bacterial infections. It includes technological platforms for drug screening, drug validation and the analysis of mechanisms of action of drugs and mechanisms of drug resistance. The program also integrates research groups from the Institut Pasteur International Network.

Organisation profile

The Institut Pasteur in Paris includes 11 research departments, more than 130 research units and junior groups, 7 technology platforms, 14 national reference centers, 9 World Health Organization collaborating centers and a teaching center. With more than 2500 people working on the Parisian campus, the Institut Pasteur, member of a network of 33 associated Institutes worldwide (the Institut Pasteur International Network, IPIN), is a unique international and multidisciplinary research organization.  The Institut Pasteur is a world leader in microbiology and immunology and in the study of the complexity of host-microbe interactions leading to infections and other diseases. Prevention and treatment of infectious diseases are among the main missions and priorities of the Institut Pasteur and of the IPIN. Resistance to antimicrobial agents is one of the three transversal priorities for the next five-year strategic plan of Institut Pasteur as defined by the recently appointed president, Stewart Cole.

The Institut Pasteur has all the competences (research units and technological platforms) for the development and the validation of new drugs to fight infections and of alternative anti-infectious strategies. They have a strong experience in public private partnership for R&D with the dedicated involvement of the Research Applications and Industrial Relations Department (DARRI) and of the Technology and Scientific Programs Department.

Contribution to the network

As an expert in bacterial physiology and in the evolution of carbapenemase-producing enterobacteriaceae, Philippe Glaser will contribute in defining priorities in drug development and in target selection. He will also be involved in defining strategies for mechanisms of action characterization and for the evaluation of the emergence of resistance. As director of the “Fighting Antibiotic Resistance” program he will ensure the communication between the network and the teams of the program and the integration of the “Fighting Antibiotic Resistance” program in the network.